1. GLP-1 receptor agonists reduced alcohol consumption in obese patients.
2.  Among those with quantifiable data, average alcohol use declined from 11.8 to 4.3 units per week. High consumers—defined as drinking 11 or more units weekly—reduced intake from 23.2 to 7.8 units.
3. There was a weak positive correlation between reduced alcohol intake and weight loss. 
4. “No patient reported an increase in alcohol intake,” the study authors noted.
5. The research provided real-world evidence supporting the drugs' potential in addressing obesity and alcohol use.

Source: Diabetes, Obesity and Metabolism